Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Change in Inventory: 2011-2024

Historic Change in Inventory for Ligand Pharmaceuticals (LGND) over the last 14 years, with Dec 2024 value amounting to -$9.6 million.

  • Ligand Pharmaceuticals' Change in Inventory fell 85.77% to -$3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.8 million, marking a year-over-year increase of 38.40%. This contributed to the annual value of -$9.6 million for FY2024, which is 188.49% down from last year.
  • According to the latest figures from FY2024, Ligand Pharmaceuticals' Change in Inventory is -$9.6 million, which was down 188.49% from $10.9 million recorded in FY2023.
  • In the past 5 years, Ligand Pharmaceuticals' Change in Inventory ranged from a high of $17.8 million in FY2020 and a low of -$12.1 million during FY2022.
  • For the 3-year period, Ligand Pharmaceuticals' Change in Inventory averaged around -$3.6 million, with its median value being -$9.6 million (2024).
  • In the last 5 years, Ligand Pharmaceuticals' Change in Inventory surged by 763.61% in 2020 and then crashed by 2,923.89% in 2022.
  • Over the past 5 years, Ligand Pharmaceuticals' Change in Inventory (Yearly) stood at $17.8 million in 2020, then slumped by 97.60% to $427,000 in 2021, then crashed by 2,923.89% to -$12.1 million in 2022, then surged by 190.15% to $10.9 million in 2023, then slumped by 188.49% to -$9.6 million in 2024.